Metformin in Modern Medicine: A Comprehensive Review of its Pharmacological Profile, Mechanisms, and Expanding Therapeutic Horizons

Abstract

Metformin, a biguanide antihyperglycemic agent, has remained a cornerstone in the management of type 2 diabetes mellitus (T2D) for decades. Its unique pharmacological profile, encompassing potent glucose-lowering effects without promoting weight gain or hypoglycemia, distinguishes it among antidiabetic therapies. Recent advances have extended its potential use into fields such as oncology, anti-aging research, and metabolic syndrome. This review synthesizes the chemical structure, pharmacokinetics, pharmacodynamics, mechanism of action, clinical applications, adverse effects, and emerging research on metformin, reflecting its evolving role in contemporary medicine.

Keywords

Introduction

Diabetes mellitus, a chronic metabolic disease characterized by hyperglycemia, affects an estimated 589 million adults globally, with type 2 diabetes (T2D) accounting for over 90% of cases. The burden of complications—including retinopathy, nephropathy, neuropathy, and cardiovascular disease—necessitates robust therapeutic interventions. Among available pharmacotherapies, metformin, a biguanide introduced over 60 years ago, remains the first-line agent recommended by international guidelines such as the American Diabetes Association (ADA). It is highly valued for its efficacy, weight neutrality, cardiovascular benefits, and low risk of hypoglycemia. In addition to T2D management, metformin is increasingly employed in prediabetes, polycystic ovary syndrome (PCOS), and investigational uses in oncology and aging. This review provides a comprehensive analysis of metformin’s chemical, pharmacological, and clinical characteristics, highlighting its enduring and expanding role in healthcare.

Fig. No. 1: Metformin Tablets BP 500 mg

Chemical Structure And Physicochemical Properties: 

Metformin (2-[N,N-dimethylcarbamimidoyl]guanidine), chemically described as N,Ndimethylimidodicarbonimidic diamide, is a small, polar molecule with the formula C?H??N?. Administered clinically as the hydrochloride salt (C?H??N?·HCl), it exhibits a molar mass of 165.6 g/mol. Its molecular structure consists of two linked guanidine groups, contributing to its hydrophilicity and minimal lipophilicity (log P ≈ –1.4). Metformin is highly water-soluble and exhibits pKa values around 2.8 and 11.5, ensuring it remains cationic under physiological conditions. These properties govern its aqueous distribution and transporter-dependent cellular uptake, pivotal for its pharmacokinetics and mechanism of action.

Fig No. 2: chemical Structure of Metformin

Mechanisms of Action:

The primary glucose-lowering mechanism of metformin is the suppression of hepatic gluconeogenesis. Transported into hepatocytes by organic cation transporter 1 (OCT1), metformin concentrates within mitochondria, where it inhibits respiratory complex I. This inhibition reduces ATP levels, raises the AMP:ATP ratio, and activates AMP-activated protein kinase (AMPK), a central regulator of energy balance. AMPK activation downregulates gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6phosphatase, decreasing hepatic glucose output.  Beyond hepatic actions, metformin enhances peripheral glucose uptake, particularly in skeletal muscle, by promoting GLUT4 translocation and enhancing insulin sensitivity. Emerging evidence also implicates AMPK-independent pathways, including direct inhibition of fructose1,6-bisphosphatase and modulation of the gut microbiome and incretin axis. These combined mechanisms confer robust glycaemic control without inducing insulin secretion, thereby minimizing hypoglycaemia risk.

Pharmacokinetics and Pharmacodynamics:

Metformin exhibits incomplete gastrointestinal absorption (40–60% bioavailability) mediated by saturable transporters, reaching peak plasma concentrations within 2–3 hours for immediate-release and 7–8 hours for extended-release formulations. It distributes widely, with an apparent volume of distribution approximating 654 L, and binds minimally to plasma proteins. Notably, metformin undergoes negligible hepatic metabolism and is excreted unchanged via renal filtration and tubular secretion (primarily through OCT2 and MATE1/2 transporters).

The drug’s half-life is approximately 6 hours in plasma and longer (~17 hours) in erythrocytes, necessitating twice-daily dosing for immediate-release forms, though extended-release preparations permit once-daily regimens. Clinically, metformin monotherapy reduces haemoglobin A1c (HbA1c) by an average of 1.0–1.5%, with maximal glycaemic effects at doses around 2,000 mg/day.

THERAPEUTIC APPLICATIONS: 

Primary Indications: Metformin remains the gold standard for initial     pharmacotherapy in T2D, particularly among overweight or obese individuals and those with cardiovascular risk factors. It is efficacious as monotherapy or in combination with other agents such as sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors.

Secondary Uses: Metformin’s benefits extend to prediabetes, where it delays progression to overt diabetes among high-risk individuals. In PCOS, it improves insulin resistance, restores menstrual regularity, and supports ovulation induction. Though utilized off-label in gestational diabetes, insulin remains the first-line therapy during pregnancy. Investigational roles include applications in non-alcoholic fatty liver disease (NAFLD), cancer prevention, cardiovascular risk reduction, and geroprotection, underpinned by its anti-inflammatory and metabolic modulating effects.

ADVERSE EFFECTS AND SAFETY CONSIDERATIONS: 

The most common adverse effects of metformin are gastrointestinal, including diarrhea, nausea, vomiting, and abdominal discomfort, reported in up to 20% of users. Slow dose titration and use of extended-release formulations mitigate these symptoms.  

Lactic acidosis, although extremely rare (<0.03 cases per 1000 patient-years), remains the most serious adverse event. Risk factors include renal impairment, congestive heart failure, hepatic dysfunction, and conditions causing hypoxia or dehydration. Consequently, renal function monitoring (eGFR assessments) is mandatory before and during therapy. Long-term use is associated with vitamin B?? deficiency, potentially leading to neuropathy and anemia, warranting periodic screening. Weight neutrality or modest reduction is a desirable secondary effect in overweight patients.

Drug Interactions and Contraindications: 

Metformin’s interaction profile is favourable, with minimal cytochrome P450 involvement. However, caution is required with cationic drugs (e.g., cimetidine, trimethoprim) that compete for renal tubular secretion, elevating metformin plasma levels.

Use of iodinated contrast agents mandates temporary discontinuation of metformin to avoid lactic acidosis. Similarly, acute illnesses, surgeries, or interventions affecting renal function necessitate metformin withholding. Contraindications include severe renal dysfunction (eGFR <30 mL/min/1.73 m²), active metabolic acidosis, and significant hepatic impairment.

RECENT ADVANCES AND RESEARCH DIRECTIONS: 

Recent innovations include the development of extended-release (XR) and delayed-release (DR) metformin formulations, improving gastrointestinal tolerability and adherence. Combination therapies with newer antidiabetic classes, such as SGLT2 inhibitors and GLP-1 analogs, offer synergistic benefits.

Investigations into metformin’s role in oncology have highlighted potential anti-proliferative effects through AMPK activation and inhibition of mTOR signalling. The TAME (Targeting Aging with Metformin) trial is evaluating its impact on aging and age-related diseases, including cardiovascular and neurodegenerative disorders. Advances in pharmacogenomics are also exploring OCT1 genetic variants as determinants of individual response to metformin therapy.

CONCLUSION: 

Metformin remains unparalleled as a first-line therapeutic agent for T2D, with a remarkable balance of efficacy, safety, and cost-effectiveness. Its expanding indications in metabolic disorders, oncology, and geriatric medicine underscore its versatility. Ongoing research into novel formulations, combination regimens, and mechanistic pathways promises to refine and extend its clinical utility further. As an archetype of repurposed therapeutics, metformin exemplifies how an "old" drug can maintain and even expand relevance in modern medicine.

REFERENCES

1. 1. 1. 1. World Health Organization. Diabetes Fact Sheet. WHO, 2024.
         2. International Diabetes Federation. IDF Diabetes Atlas, 11th Edition. 2025.
         3. Bailey CJ. Metformin: Historical Overview. Diabetologia. 2017;60(9):1566–1576.
         4. Scheen AJ. Clinical Pharmacokinetics of Metformin. Clin Pharmacokinet. 1996;30(5):359–371.
         5. Additional peer-reviewed sources (recent research up to 2025). Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. Diabetologia, 60(9), 1577–1585. https://doi.org/10.1007/s00125-017-4342-z
         6. Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014). Metformin: from mechanisms of action to therapies. Cell Metabolism, 20(6), 953–966. https://doi.org/10.1016/j.cmet.2014.09.018
         7. UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet, 352(9131), 854–865. https://doi.org/10.1016/S0140-6736(98)07037-8
         8. Nathan, D. M., et al. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care, 32(1), 193–203. https://doi.org/10.2337/dc08-9025
         9. Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012). Cellular and molecular mechanisms of metformin: an overview. Clinical Science, 122(6), 253–270. https://doi.org/10.1042/CS20110386
         10. American Diabetes Association (ADA). (2025). Standards of Medical Care in Diabetes—2025. Diabetes Care, 48(Suppl 1). https://doi.org/10.2337/dc25-S001 11) Lalau, J. D., & Silvestre, J. (2022). Metformin and lactic acidosis: a reappraisal. Metabolism, 133, 155233. https://doi.org/10.1016/j.metabol.2022.155233
         11. Nasri, H., & Rafieian-Kopaei, M. (2014). Metformin: current knowledge. Journal of
         12. Research in Medical Sciences, 19(7), 658–664. PubMed Central link
         13. Barzilai, N., et al. (2016). Metformin as a tool to target aging. Cell Metabolism, 23(6), 1060–1065. https://doi.org/10.1016/j.cmet.2016.05.011